All In Biotech

Drug Trial Radar · NCT06784648

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

An Open-Label, Multicentre Phase 1B/2A Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32B) in Combination With Ipilimumab and Pembrolizumab in Participants With Unresectable or Metastatic Melanoma

Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Dec 11, 2024

Primary completion

Sep 9, 2026

Study completion Jul 30, 2027

Sponsor

Lead sponsor
BioInvent International ABIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jan 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically. Melanoma is a type of skin cancer that starts in melanocytes, the cells that make the pigment that gives skin its color. In people with cancer, the body cannot control the growth of cells, which can come together to form tumors. This trial's new treatment is called BI-1607. BI-1607 is designed to work by improving the effectiveness of other targeted therapies already used for melanoma treatment; ipilimumab and pembrolizumab. BI-1607 will improve the ability of these two treatments to help the body's defense system to destroy cancer cells.

Conditions

  • Melanoma Metastatic
  • Melanoma of Skin
  • Melanoma BRAF V600E/K Mutated
  • Melanoma Recurrent
  • Melanoma Stage III or IV
  • Melanoma
  • Melanoma Negative for bRAF
  • Melanoma Negative for nRAS
  • Melanomas
  • Uveal Melanoma, Metastatic

Interventions

  • pembrolizumab (KEYTRUDA®)Biological

    fixed dose 200mg

  • BI-1607Biological

    Each cohorts will receive either 350mg or 700mg per cycle for 4 cycles

  • Ipilimumab (YervoyTM, 50 mg/10 mL solution)Biological

    Each cohort will receive either 1mg/kg or 3mg/kg for 4 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
  2. Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
  3. Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
  4. Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
  5. Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
  6. Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
  7. Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
  8. Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)
  9. Recommended doses for the expansion cohortTime frame: End of Cycle 3 (each cycle is 21 days)
  10. EfficacyTime frame: Through study completion, a maximum of 2 years
  11. EfficacyTime frame: Through study completion, a maximum of 2 years
  12. EfficacyTime frame: Through study completion, a maximum of 2 years
  13. EfficacyTime frame: Through study completion, a maximum of 2 years
  14. EfficacyTime frame: Through study completion, a maximum of 2 years
  15. EfficacyTime frame: Through study completion, a maximum of 2 years
  16. Safety and tolerabilityTime frame: end of Cycle 4 (each cycle is 21 days)

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • University Hospital Heidelberg

    Heidelberg, Germany

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • University Hospital 12 de Octubre

    Madrid, Spain

  • Sarah Cannon Research Institute UK

    London, Greater London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.